Aberrant expression of m6A mRNA methylation regulators in colorectal adenoma and adenocarcinoma

Dayu, Kuai; Zhu, Shoumin; Shi, Haiyun; Yang, Ruihua; Liu, Tong; Liu, Hui; Li, Min; Zhang, Shutian

doi:10.1016/j.lfs.2021.119258

Cited by 21 publications

(16 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…m6A Readers, ICIs in CRC Numerous studies on m6A Reader have confirmed four genes (YTHDF1, IGF2BP1, IGF2BP1, IGFBP3, EIF3B) is a potential biomarker of CRC. It was found to downregulate YTHDF1 or IMP2, can further regulate the GLS1-glutamine metabolic axis, improve the stability of the m6A-modified GSK3b mRNA, inhibition of Wnt/-catenin/cyclin D1 expression, inhibition of CRC cell proliferation, colony formation, and increase the apoptosis levels in CRC cells, To sensitized cisplatin-resistant CRC cells (126)(127)(128).…”

Section: M6a Modification Icis In Crcmentioning

confidence: 99%

The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors

Tong

Smith

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Tumor immunotherapy, one of the efficient therapies in cancers, has been called to the scientific community’s increasing attention lately. Among them, immune checkpoint inhibitors, providing entirely new modalities to treat cancer by leveraging the patient’s immune system. They are first-line treatments for varieties of advanced malignancy, such as melanoma, gastrointestinal tumor, esophageal cancer. Although immune checkpoint inhibitors (ICIs) treatment has been successful in different cancers, drug resistance and relapses are common, such as in colorectal cancer. Therefore, it is necessary to improve the efficacy of immune checkpoint therapy for cancer patients who do not respond or lowly response to current treatments. N6-methyladenosine (m6A), as a critical regulator of transcript expression, is the most frequently internal modification of mRNA in the human body. Recently, it has been proposed that m6A epigenetic modification is a potential driver of tumor drug resistance. In this report, we will briefly outline the relevant mechanisms, general treatment status of immune checkpoint inhibitors in colorectal cancer, how m6A epigenetic modifications regulate the response of ICIs in CRC and provide new strategies for overcoming the resistance of ICIs in CRC.

show abstract

Section: M6a Modification Icis In Crcmentioning

confidence: 99%

The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors

Tong

Smith

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Beyond the methyltransferases, the “readers” that can recognize m 6 A modulation sites, such as YTHDF1 , IGF2BP1 , IGF2BP3 , and EIF3B ( 151 ), are also under the influence of ncRNAs. The tumor-suppressive miR-1266 promoted the occurrence and progression of CRCs by directly targeting FTO ( 152 ).…”

Section: The Role Of M6a Methylation Of Rnas In Emtmentioning

confidence: 99%

The Interaction Between Epigenetic Changes, EMT, and Exosomes in Predicting Metastasis of Colorectal Cancers (CRC)

2022

View full text Add to dashboard Cite

Worldwide, colorectal cancer (CRC) ranks as the third most common malignancy, and the second most deadly with nearly one million attributable deaths in 2020. Metastatic disease is present in nearly 25% of newly diagnosed CRC, and despite advances in chemotherapy, less than 20% will remain alive at 5 years. Epigenetic change plays a key role in the epithelial-to-mesenchymal transition (EMT), which is a crucial phenotype for metastasis and mainly includes DNA methylation, non-coding RNAs (ncRNAs), and N6-methyladenosine (m6A) RNA, seemingly valuable biomarkers in CRCs. For ncRNAs, there exists a “molecular sponge effect” between long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), and microRNAs (miRNAs). The detection of exosomes is a novel method in CRC monitoring, especially for predicting metastasis. There is a close relationship between exosomes and EMT in CRCs. This review summarizes the close relationship between epigenetic changes and EMT in CRCs and emphasizes the crucial function of exosomes in regulating the EMT process.

show abstract

“…Furthermore, studies have shown that m 6 A methylation modification is closely related to the activation and inhibition of cancer-related signaling pathways, which mainly affect tumor progression by regulating related tumor biological functions ( 6 ). At present, m 6 A RNA modification is increasingly used in cancer detection and related targeted molecules ( 7 , 8 ).…”

Section: Overview Of M 6 a Methylationmentioning

confidence: 99%

Effects of N6-Methyladenosine Modification on Cancer Progression: Molecular Mechanisms and Cancer Therapy

et al. 2022

View full text Add to dashboard Cite

N6-methyladenosine (m6A) is a major internal epigenetic modification in eukaryotic mRNA, which is dynamic and reversible. m6A is regulated by methylases (“writers”) and demethylases (“erasers”) and is recognized and processed by m6A-binding proteins (“readers”), which further regulate RNA transport, localization, translation, and degradation. It plays a role in promoting or suppressing tumors and has the potential to become a therapeutic target for malignant tumors. In this review, we focus on the mutual regulation of m6A and coding and non-coding RNAs and introduce the molecular mechanism of m6A methylation involved in regulation and its role in cancer treatment by taking common female malignant tumors as an example.

show abstract

Aberrant expression of m6A mRNA methylation regulators in colorectal adenoma and adenocarcinoma

Cited by 21 publications

References 38 publications

The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors

The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors

The Interaction Between Epigenetic Changes, EMT, and Exosomes in Predicting Metastasis of Colorectal Cancers (CRC)

Effects of N6-Methyladenosine Modification on Cancer Progression: Molecular Mechanisms and Cancer Therapy

Contact Info

Product

Resources

About